Business
Uruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research
Uruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research.
About this update from Plandai Biotechnology, Inc.
[{"type":"text","content":"\nUruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research\n\nUruguay's Presidential Election Favors Plandai Biotechnology's Future Cannabis Research\n\nNEW YORK, NY--(Marketwired - December 04, 2014) - Timing is everything and when Plandaí Biotechnology (OTCQB: PLPL) was given the go-ahead to grow cannabis for medical research in Uruguay, little did they know then that a Presidential runoff in that country would be of great interest today. Plandaí got the green light back in September from Uruguay's Minister of Public Health to collaborate with the Group of Medicinal Chemistry from the School of Science at the University of the Republic in Montevideo.  Permission was granted to Plandaí by a government that has developed a plan to regulate the production, distribution and sale of marijuana nationwide. Uruguay's government under President Jose Mujica of the Broad Front Coalition was clearly friendly to the future of cannabis in that country, and Tabare Vazquez, also of the Broad Front Coalition, promised to continue the liberal cannabis policy.  But, in Sunday's election, a member of the opposition party promised to undo the plan. When the dust finally settled, the State-run cannabis plan survived as Vazquez, who is an oncologist, handily won the Presidency 53 percent to 40 percent. This is, of course, good news to Plandaí's own plan which includes a collaboration that will allow Plandaí, through its wholly owned subsidiary Plandaí Biotechnology - Uruguay, SA, to grow cannabis in conjunction with the University of the Republic, for medical research, which will be conducted by students and scientists from the School of Science at the University. Plandaí can continue with its plan to now legally grow cannabis, and not just CBD dominant strains of the plant. The company's plan then calls for clinical testing using the drug.  The first phase of the project will establish the infrastructure and protocols for growing the cannabis in a controlled environment to ensure genetic purity and chemical consistency. Due to the ongoing controversy about the growth and availability of medicinal cannabis in many parts of the US, as well as the ability to conduct US testing on the medicinal effectiveness of cannabis, many patients who might benefit ...